Literature DB >> 19451241

Identification of a simple chemical structure associated with protective human antibodies against multiple pneumococcal serogroups.

Saeyoung Park1, Archana R Parameswar, Alexei V Demchenko, Moon H Nahm.   

Abstract

Streptococcus pneumoniae, a major human pathogen, expresses at least 91 serologically distinct carbohydrate capsules. Since pneumococcal vaccines are designed to elicit antibodies against many different capsular polysaccharides (PSs), it is important to identify the epitopes involved in eliciting anti-capsular PS antibodies. We investigated the epitopes recognized by Dob1, which is a hybridoma-secreting human immunoglobulin G2 antibody to the PS of serotype 6B (Y. Sun et al., Infect. Immun. 67:1172-1179, 1999). We found that Dob1 bound synthetic capsular carbohydrates Gal(1-->3)alpha-d-Glcp(1-->3)alpha-l-Rhap(1-->3)Rib-ol and alpha-d-Glcp(1-->3)alpha-l-Rhap(1-->3)Rib-ol but did not bind alpha-l-Rhap(1-->3)Rib-ol. The critical epitope alpha-d-Glcp(1-->3)alpha-l-Rhap is found in the capsular PSs of serotypes 6A, 6B, 6C, and 19A but not in the 19F PS. Consistent with this observation, Dob1 bound to the PSs of serotypes 6A, 6B, 6C, and 19A but did not bind the 19F PS and 23 additional unrelated pneumococcal capsular PSs. Also, Dob1 could opsonize pneumococci expressing serotypes 6A, 6B, 6C, and 19A but did not opsonize 19F pneumococci. In addition, ca. 7% of immune sera (12 of 175 sera) had significant amounts of Dob1-like antibodies, i.e., reacted with 6B and 19A PSs, but not with 19F PS. Humans can produce antibodies to the Dob1 epitope and the antibodies to that epitope cross-react with the four serotypes 6A, 6B, 6C, and 19A that belong to different serogroups. This epitope may be useful for producing a totally synthetic, simple chemical structure that is capable of generating protective antibodies to multiple pneumococcal serogroups.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19451241      PMCID: PMC2715663          DOI: 10.1128/IAI.00319-09

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  29 in total

1.  Cross-reactivity of antibodies to type 6B and 6A polysaccharides of Streptococcus pneumoniae, evoked by pneumococcal conjugate vaccines, in infants.

Authors:  M Väkeväinen; C Eklund; J Eskola; H Käyhty
Journal:  J Infect Dis       Date:  2001-08-14       Impact factor: 5.226

2.  Population snapshot of Streptococcus pneumoniae serotype 19A isolates before and after introduction of seven-valent pneumococcal Vaccination for French children.

Authors:  Farah Mahjoub-Messai; Catherine Doit; Jean-Louis Koeck; Typhaine Billard; Bénédicte Evrard; Philippe Bidet; Christine Hubans; Josette Raymond; Corinne Levy; Robert Cohen; Edouard Bingen
Journal:  J Clin Microbiol       Date:  2008-12-24       Impact factor: 5.948

3.  Synthesis of spacer-containing analogs of serogroup 6 pneumococcal oligosaccharides.

Authors:  Archana R Parameswar; Scott J Hasty; Alexei V Demchenko
Journal:  Carbohydr Res       Date:  2008-04-04       Impact factor: 2.104

4.  Synthetic 6B di-, tri-, and tetrasaccharide-protein conjugates contain pneumococcal type 6A and 6B common and 6B-specific epitopes that elicit protective antibodies in mice.

Authors:  W T Jansen; S Hogenboom; M J Thijssen; J P Kamerling; J F Vliegenthart; J Verhoef; H Snippe; A F Verheul
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

5.  Synthetic polysaccharide type 3-related di-, tri-, and tetrasaccharide-CRM(197) conjugates induce protection against Streptococcus pneumoniae type 3 in mice.

Authors:  B Benaissa-Trouw; D J Lefeber; J P Kamerling; J F Vliegenthart; K Kraaijeveld; H Snippe
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

6.  Revised interpretation of the immunological results obtained with pneumococcal polysaccharide 17F derived synthetic di-, tri- and tetrasaccharide conjugates in mice and rabbits.

Authors:  W T Jansen; A F Verheul; G H Veeneman; J H van Boom; H Snippe
Journal:  Vaccine       Date:  2001-10-12       Impact factor: 3.641

7.  Changes of serotype and genotype in Streptococcus pneumoniae isolates from a Korean hospital in 2007.

Authors:  Jae-Hoon Song; Jin Yang Baek; Hae Suk Cheong; Doo Ryeon Chung; Kyong Ran Peck; Kwan Soo Ko
Journal:  Diagn Microbiol Infect Dis       Date:  2009-01-29       Impact factor: 2.803

8.  Differential effects of pneumococcal vaccines against serotypes 6A and 6C.

Authors:  In H Park; Matthew R Moore; John J Treanor; Stephen I Pelton; Tamara Pilishvili; Bernard Beall; Mark A Shelly; Barbara E Mahon; Moon H Nahm
Journal:  J Infect Dis       Date:  2008-12-15       Impact factor: 5.226

9.  Identification of the smallest structure capable of evoking opsonophagocytic antibodies against Streptococcus pneumoniae type 14.

Authors:  Dodi Safari; Huberta A T Dekker; John A F Joosten; Dirk Michalik; Adriana Carvalho de Souza; Roberto Adamo; Martina Lahmann; Andreas Sundgren; Stefan Oscarson; Johannis P Kamerling; Harm Snippe
Journal:  Infect Immun       Date:  2008-08-04       Impact factor: 3.441

10.  Increase in the prevalence of the newly discovered pneumococcal serotype 6C in the nasopharynx after introduction of pneumococcal conjugate vaccine.

Authors:  Moon H Nahm; Jisheng Lin; Jonathan A Finkelstein; Stephen I Pelton
Journal:  J Infect Dis       Date:  2009-02-01       Impact factor: 5.226

View more
  7 in total

1.  Opsonophagocytic activity following a reduced dose 7-valent pneumococcal conjugate vaccine infant primary series and 23-valent pneumococcal polysaccharide vaccine at 12 months of age.

Authors:  F M Russell; J R Carapetis; R L Burton; J Lin; P V Licciardi; A Balloch; L Tikoduadua; L Waqatakirewa; Y B Cheung; M L K Tang; M H Nahm; E K Mulholland
Journal:  Vaccine       Date:  2010-10-31       Impact factor: 3.641

Review 2.  Pneumococcal Capsules and Their Types: Past, Present, and Future.

Authors:  K Aaron Geno; Gwendolyn L Gilbert; Joon Young Song; Ian C Skovsted; Keith P Klugman; Christopher Jones; Helle B Konradsen; Moon H Nahm
Journal:  Clin Microbiol Rev       Date:  2015-07       Impact factor: 26.132

3.  Electrochemical Impedance Spectroscopy Study of Concanavalin A Binding to Self-Assembled Monolayers of Mannosides on Gold Wire Electrodes.

Authors:  Jay K Bhattarai; Yih Horng Tan; Binod Pandey; Kohki Fujikawa; Alexei V Demchenko; Keith J Stine
Journal:  J Electroanal Chem (Lausanne)       Date:  2016-09-28       Impact factor: 4.464

4.  Glycosyl Thioimidates as Versatile Building Blocks for Organic Synthesis.

Authors:  S J Hasty; A V Demchenko
Journal:  Chem Heterocycl Compd (N Y)       Date:  2012-04       Impact factor: 1.277

Review 5.  Panel 6: Vaccines.

Authors:  Stephen I Pelton; Melinda M Pettigrew; Stephen J Barenkamp; Fabrice Godfroid; Carlos G Grijalva; Amanda Leach; Janak Patel; Timothy F Murphy; Sanja Selak; Lauren O Bakaletz
Journal:  Otolaryngol Head Neck Surg       Date:  2013-04       Impact factor: 3.497

6.  Antibodies to Staphylococcus aureus serotype 8 capsular polysaccharide react with and protect against serotype 5 and 8 isolates.

Authors:  Saeyoung Park; Sabina Gerber; Jean C Lee
Journal:  Infect Immun       Date:  2014-09-22       Impact factor: 3.441

7.  Fully human monoclonal antibodies from antibody secreting cells after vaccination with Pneumovax®23 are serotype specific and facilitate opsonophagocytosis.

Authors:  Kenneth Smith; Jennifer J Muther; Angie L Duke; Emily McKee; Nai-Ying Zheng; Patrick C Wilson; Judith A James
Journal:  Immunobiology       Date:  2012-09-03       Impact factor: 3.144

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.